Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Myeloid 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Lymphoma 1Burkitt Lymphoma 1

Interventions

Specimen Handling 329Magnetic Resonance Spectroscopy 238Biopsy 196Nivolumab 57Cyclophosphamide 52X-Rays 49Radiation 47Paclitaxel 47Carboplatin 47Cisplatin 46pembrolizumab 45Taxes 45Immunoglobulin G 45Disulfides 45Platinum 421,2-diaminocyclohexaneplatinum II citrate 42Radiotherapy 38Doxorubicin 36Ipilimumab 32Gemcitabine 32atezolizumab 31CTLA-4 Antigen 31olaparib 28fludarabine 27venetoclax 25Vincristine 25Bevacizumab 25Prednisone 24cabozantinib 23Phantoms, Imaging 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Clofarabine × 90 days × Clear all
NCT02883049 2026-06-02

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

National Cancer Institute (NCI)

Phase 3 Completed
5,949 enrolled 28 charts
Lymphoid

Burkitt Lymphoma

NCT02211755 2026-04-28

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
28 enrolled
LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡